Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

HBPL Study of the Impact of the NK1 Antagonist Aprepitant

This study has been terminated.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jennifer Plebani, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01176591
First received: August 4, 2010
Last updated: April 2, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2013
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)